These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 16886519)

  • 21. First treatment for dementia of Parkinson's disease.
    FDA Consum; 2006; 40(5):5. PubMed ID: 17328100
    [No Abstract]   [Full Text] [Related]  

  • 22. [Lewy body dementia and Parkinson disease dementia].
    Meyniel C; Damier P
    Presse Med; 2007 Oct; 36(10 Pt 2):1485-90. PubMed ID: 17572053
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease.
    Devos D;
    Mov Disord; 2009 May; 24(7):993-1000. PubMed ID: 19253412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Hallucinations associated to treatment with rivastigmine in two patients with diffuse Lewy body disease].
    Alonso-Navarro H; Jiménez-Jiménez FJ
    Rev Neurol; 2007 May 1-15; 44(9):575-6. PubMed ID: 17492618
    [No Abstract]   [Full Text] [Related]  

  • 25. Subthalamic nucleus stimulation does not cause deterioration of preexisting hallucinations in Parkinson's disease patients.
    Yoshida F; Miyagi Y; Kishimoto J; Morioka T; Murakami N; Hashiguchi K; Samura K; Sakae N; Yamasaki R; Kawaguchi M; Sasaki T
    Stereotact Funct Neurosurg; 2009; 87(1):45-9. PubMed ID: 19174620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rivastigmine in Parkinson's disease dementia: profile report.
    Siddiqui MA; Wagstaff AJ
    Drugs Aging; 2007; 24(3):255-9. PubMed ID: 17362052
    [No Abstract]   [Full Text] [Related]  

  • 27. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial.
    Reading PJ; Luce AK; McKeith IG
    Mov Disord; 2001 Nov; 16(6):1171-4. PubMed ID: 11748755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia.
    Cummings J; Winblad B
    Expert Rev Neurother; 2007 Nov; 7(11):1457-63. PubMed ID: 17997695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Features associated with the development of hallucinations in Parkinson's disease.
    Benbir G; Ozekmekçi S; Cinar M; Beskardes F; Apaydin H; Erginöz E
    Acta Neurol Scand; 2006 Oct; 114(4):239-43. PubMed ID: 16942542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antidepressant use in treatment of psychosis with comorbid depression in Parkinson's disease.
    Meco G; Bernardi S
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):311-3. PubMed ID: 16919377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rivastigmine: new indication. Dementia and Parkinson's disease: no thank you!
    Prescrire Int; 2007 Apr; 16(88):66. PubMed ID: 17458048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Neuropsychiatric and cognitive symptoms in Parkinson disease].
    Aarsland D; Pedersen KF; Ehrt U; Bronnick K; Gjerstad MD; Larsen JP
    Tidsskr Nor Laegeforen; 2008 Sep; 128(18):2072-6. PubMed ID: 18846124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of responders and reactive domains to rivastigmine in Alzheimer's disease.
    Frankfort SV; Appels BA; de Boer A; Tulner LR; van Campen JP; Koks CH; Beijnen JH; Schmand BA
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):545-51. PubMed ID: 17109476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between the efficacy of rivastigmine and apolipoprotein E (epsilon4) in patients with mild to moderately severe Alzheimer disease.
    Blesa R; Aguilar M; Casanova JP; Boada M; Martínez S; Alom J; de la Hoz CH; Sancho J; Fernández O; Gil-Neciga E; Massó JF
    Alzheimer Dis Assoc Disord; 2006; 20(4):248-54. PubMed ID: 17132969
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis.
    Merims D; Balas M; Peretz C; Shabtai H; Giladi N
    Clin Neuropharmacol; 2006; 29(6):331-7. PubMed ID: 17095896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New approaches to understanding hallucinations in Parkinson's disease: phenomenology and possible origins.
    Onofrj M; Thomas A; Bonanni L
    Expert Rev Neurother; 2007 Dec; 7(12):1731-50. PubMed ID: 18052766
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug selection and timing of initiation of treatment in early Parkinson's disease.
    Schapira AH; Olanow CW
    Ann Neurol; 2008 Dec; 64 Suppl 2():S47-55. PubMed ID: 19127579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adherence to antiparkinson medication in a multicenter European study.
    Grosset D; Antonini A; Canesi M; Pezzoli G; Lees A; Shaw K; Cubo E; Martinez-Martin P; Rascol O; Negre-Pages L; Senard A; Schwarz J; Strecker K; Reichmann H; Storch A; Löhle M; Stocchi F; Grosset K
    Mov Disord; 2009 Apr; 24(6):826-32. PubMed ID: 19191340
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rivastigmine for minor visual hallucinations in Parkinson's disease: A randomized controlled trial with 24 months follow-up.
    van Mierlo TJM; Foncke EMJ; Post B; Schmand BA; Bloem BR; van Harten B; Tissingh G; Munts AG; de Haan RJ; de Bie RMA;
    Brain Behav; 2021 Aug; 11(8):e2257. PubMed ID: 34291590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.